Abstract |
Imiquimod, an immune response modifier with potent antiviral and antitumor properties, has been reported to be effective in the treatment of various cutaneous neoplasms. Besides stimulating the production of pro-inflammatory cytokines through Toll-like receptors on the surface of dendritic cells of monocyte-macrophage lineage, novel antiapoptotic mechanisms have been identified.
|
Authors | Rafael F Martín-García |
Journal | Journal of drugs in dermatology : JDD
(J Drugs Dermatol)
2004 May-Jun
Vol. 3
Issue 3
Pg. 247-9
ISSN: 1545-9616 [Print] United States |
PMID | 15176157
(Publication Type: Journal Article, Review)
|
Chemical References |
- Adjuvants, Immunologic
- Aminoquinolines
- Antineoplastic Agents
- Membrane Glycoproteins
- Receptors, Cell Surface
- Toll-Like Receptors
- Imiquimod
|
Topics |
- Adjuvants, Immunologic
(administration & dosage, pharmacology, therapeutic use)
- Administration, Cutaneous
- Aminoquinolines
(administration & dosage, pharmacology, therapeutic use)
- Antineoplastic Agents
(administration & dosage, pharmacology, therapeutic use)
- Apoptosis
(drug effects)
- Humans
- Imiquimod
- Membrane Glycoproteins
(agonists, metabolism)
- Receptors, Cell Surface
(agonists, metabolism)
- Skin Neoplasms
(drug therapy)
- Toll-Like Receptors
|